



21st ANNUAL INDUSTRY/ACADEMIA PRECISION ONCOLOGY & RADMED SYMPOSIUM

NOVEMBER 5, 2025 | 8AM - 6PM | THE ALEXANDRIA AT TORREY PINES

Morning Agenda

- 7:30 **Registration and Networking Breakfast**
Location: Helvetica
- 8:30 **Welcome Remarks**
Location: Illumina Theater
Arno J. Mundt, MD, FACRO, FASTRO, Professor and Founding Chair, Radiation Medicine and Applied Sciences, Executive Governing Committee, Moores Cancer Center, UC San Diego
Ida Deichaite, PhD, Assistant Professor, Radiation Medicine and Applied Sciences, UC San Diego
- Session Title: AI**
Time: 8:45 – 10:20 | **Location:** Illumina Theater
Session Chairs:
Sandip Patel, MD, Professor, Deputy Director, Sanford Stem Cell Clinical Institute, Medical Director, Clinical Research Informatics, Moores Cancer Center, UC San Diego
Paul Rejto, PhD, Vice President, Discovery Technologies, Pfizer
- 8:45 **Digital Tumors for Precision Oncology**
Trey Ideker, PhD, Professor, Department of Medicine, Adjunct Professor, Departments of Bioengineering and Computer Science, UC San Diego
- 8:55 **AI/ML for Forward/Reverse Translation**
Jadwiga Bienkowska, PhD, Senior Director, Head of Computational Biology, Oncology Research & Development, Pfizer
- 9:05 **Omnimodal AI for Precision Oncology: Integrating Data to Drive Discovery**
Nathan Fowler, MD, Chief Medical Officer, BostonGene
- 9:15 **AI Enables Rapid Identification of Targeted Cancer Therapy**
Rick Fultz, Chief Executive Officer, Board Member, Acurion
- 9:25 **From Models to Medicines: Delivering on the Promise of AI-Driven Drug Discovery**
Tom Miller, PhD, Co-Founder, Chief Executive Officer, Iambic Therapeutics
- 9:35 **AI-Guided Proteogenomics for Precision Oncology: Decoding Therapeutic Response in AML**
Pilgrim Jackson, PhD, Founder, Chief Executive Officer, Yatiri Bio
- 9:45 Q&A and Panel Discussion
- 10:20 **Break**
Location: Helvetica
- 10:40 **Powering Early-Stage Drug Discovery with AI/ML & Community**
Vanessa Braunstein, Senior Director, TuneLab AI Drug Discovery Platform, Lilly
Kathleen Lin, PhD, Senior Director, Site Head, Lilly Gateway Labs San Diego
- Session Title: Precision Oncology through Targeted Protein Degradation Mechanisms**
Time: 11:00 – 12:15 | **Location:** Illumina Theater
Session Chairs:
Eric Bennett, PhD, Professor, Department of Cell and Developmental Biology, UC San Diego
Phil Chamberlain, DPhil, Co-Founder, President, and CEO, Neomorph
- 11:00 **ZBTB11 Depletion Targets Metabolic Vulnerabilities in K-Ras Inhibitor Resistant PDAC**
Fleur Ferguson, PhD, Assistant Professor, Department of Chemistry & Biochemistry, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego
- 11:10 **Expanding the scope of molecular glues into new targets and indications**
Phil Chamberlain, DPhil, Co-Founder, President, and CEO, Neomorph
- 11:20 **The Proteostasis Network is a Therapeutic Target in Acute Myeloid Leukemia**
Robert Signer, PhD, Deputy Director, Stem Cell Discovery Center, Associate Professor of Medicine, Division of Regenerative Medicine, Sanford Stem Cell Institute, UC San Diego
- 11:30 **Advancing Novel Precision Oncology Therapeutics with Monovalent Targeted Protein Degraders**
Michael Martin, PhD, Chief Executive Officer, Plexium
- 11:40 Q&A and Panel Discussion
- 12:15 **Lunch and Poster Session**
Location: Americana Room

Scan to learn about our



Symposium Speakers



21st ANNUAL INDUSTRY/ACADEMIA PRECISION ONCOLOGY & RADMED SYMPOSIUM

NOVEMBER 5, 2025 | 8AM - 6PM | THE ALEXANDRIA AT TORREY PINES

Afternoon Agenda

Session Title: **Next-Gen Targeted and Immune Therapies**

Time: 1:25 – 2:25 | Location: Illumina Theater

Session Chairs:

Analeah Heidt, PhD, Chief Scientific Officer, Enlaza Therapeutics

Shweta Joshi, PhD, Assistant Professor, Department of Pediatrics, Moores Cancer Center, UC San Diego

1:25 ***Darlifarnib- bench to bedside development of a next-gen FTI in combination with cabozantinib in RCC***
Francis Burrows, PhD, Chief Scientific Officer, Kura Oncology

1:35 ***HER3-Targeted Antibody-Drug Conjugates for IO Combination Therapy***
J. Silvio Gutkind, PhD, Chair, Department of Pharmacology, Moores Cancer Center, UC San Diego

1:45 ***DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal Cancer and Ewings Sarcoma***
Josep Garcia, PhD, Executive Vice President, Chief Clinical Development Officer, Inhibrx
Katelyn Willis, PhD, Research Director, Biotherapeutics, Inhibrx

1:55 Q&A and Panel Discussion

Session Title: **Duane Roth Achievement Award**

Time: 2:25 – 2:45 | Location: Illumina Theater

Lecture Title: ***Integrating radiopharmaceuticals in combined modality treatments for cancer***

Recipient:

Catheryn Yashar, MD, FACRO, FABS, FACR, FASTRO, Professor & Vice Chair of Clinical Affairs, Division of Radiation Oncology, Radiation Medicine and Applied Sciences, Chief Medical Officer, Health System, UC San Diego

2:45 **Break**

Location: Helvetica

Session Title: **Radiopharmaceuticals**

Time: 3:05 – 5:15 | Location: Illumina Theater

Session Chairs:

Jake Haling, PhD, Head, Oncology Drug Discovery, San Diego, Novartis Biomedical Research

Andrew Sharabi, MD, PhD, Professor & Jacobs Chancellor's Endowed Chair in Radiation, Medicine and Applied Sciences, Director, Center for Precision Radiation Medicine, Moores Cancer Center, UC San Diego

3:05 ***Integrating radiopharmaceuticals in combined modality treatments for cancer***

Zachary Morris, MD, PhD, Endowed Paul Harari Professor, Chair, Department of Human Oncology, University of Wisconsin School of Medicine and Public Health

3:15 ***The landscape of opportunities for combining theranostics and radiotherapy in prostate cancer***

Tyler Seibert, MD, PhD, Associate Professor, Division of Radiation Oncology, Co-Director, UC San Diego Center for Translational Imaging, Departments of Radiation Medicine and Applied Sciences; Urology; Radiology; and Bioengineering, Moores Cancer Center, UC San Diego

3:25 ***Targeting Tumor Microenvironment with Radioligands***

Frederic Zecri, PhD, Chief Scientific Officer, Mariana Therapeutics, a Novartis Company

3:35 ***Targeted alpha therapy with ²¹²Pb, a short-lived isotope with long-lived benefit***

Gary Li, PhD, Chief Strategy Officer, AdvanCell

3:45 ***Pioneering aRPT: Opportunities for Collaboration***

Eileen Sneed, PhD, Senior Director, Radiation Biophysics & Nuclear Oncology Liaison, RayzeBio, a Bristol Myers Squibb Company

3:55 ***Expanding Access to Radioligand Therapies: Reaching every Patient, Everywhere***

Brent Rose, MD, Associate Professor, Director, Division of Radiation Oncology, Department of Radiation Medicine and Applied Sciences, UC San Diego

4:05 ***AI-Based Automated Planning for Breast Radiotherapy: A Precision Individualized Approach***

Lance Moore, MS, Computational and Data Science Researcher, Department of Radiation Medicine and Applied Sciences, UC San Diego

4:15 Q&A and Panel Discussion

5:15 **Closing Remarks**

Andrew Sharabi, MD, PhD, Professor & Jacobs Chancellor's Endowed Chair in Radiation, Medicine and Applied Sciences, Director, Center for Precision Radiation Medicine, Moores Cancer Center, UC San Diego

5:20 **Networking Reception and Poster Session**

Location: Americana Room

Scan to learn about the



**Duane Roth
Achievement Award**